Generated: May 28, 2017
|Title:||Paroxetine controlled release compositions|
|Abstract:||A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.|
|Inventor(s):||Leonard; Graham Stanley (St. Albans, GB), Elder; David Philip (Hertford, GB)|
|Assignee:||SmithKline Beecham p.l.c. (Brentford, GB)|
1. A composition, that reduces the incidence of nausea and vomiting associated with the administration of paroxetine, comprising paroxetine, or a pharmaceutically acceptable
salt thereof, in a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases the paroxetine predominantly in the small intestine.
2. A method of treating one or more disease states selected from; Alcoholism, Anxiety, Depression, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymla and Substance Abuse, which comprises administering an effective amount of a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases paroxetine or a pharmaceutically acceptable salt thereof, predominantly in the small intestine to an individual in need thereof.